CML Treatment Failure: More Threatening Than It Appears. Mutation Testing
|
|
- Geraldine Lauren Hancock
- 6 years ago
- Views:
Transcription
1 CML Treatment Failure: More Threatening Than It Appears Mutation Testing
2 Content Mutations and treatment failure Single mutations Compound mutations Mutation testing Guideline recommendations Summary 2
3 Mutations and Treatment Failure
4 BCR-ABL1 mutation can confer TKI resistance and is a mechanism of treatment failure in CML Resistance BCR-ABL1 Mutation (~40%) 1,2 Others (~60%) Activation of SRC family kinases 3 Drug-drug interactions 4 BCR-ABL1 dependent Drug binding, inadequate drug concentration, or epigenetic modifications 3 Increased drug efflux or influx 3,5 Inability of TKIs to eradicate mutant stem cells or cross the blood-brain barrier 6,7 BCR-ABL1 independent BCR-ABL1 gene amplification 3 1. Soverini S, et al. Clin Cancer Res. 2006;12: Cortes J, et al. Blood. 2007;109: Bixby D, et al. Leukemia. 2011;25: Bowlin SJ, et al. ASCPT Quintás-Cardama A, et al. Cancer Control. 2009;16: Valent P. Biologics. 2007; 1: Corbin AS, et al. J Clin Invest. 2011;12:
5 How do BCR-ABL1 mutations emerge? Mutations can occur in cancer cells where genetic instability is high and accumulation of further abnormalities is likely 1,2 TKI therapy can select for BCR-ABL1 mutations in unstable cancer cells Small cell populations containing mutations may have a survival advantage during TKI therapy and emerge later as the dominant clone 1,2 In an in vitro simulation, sequential use of TKIs increases the probability that mutations will arise, and the sequence of TKIs used may influence the types of mutations that emerge 3 Sensitive to TKI Resistant to TKI Treat with TKI Sensitive to TKI Resistant to TKI 1. Soverini S, et al. Blood. 2011;118: Sierra JR, et al. Molec Cancer. 2010;9: Bauer RC, et al. Clin Cancer Res. 2013;19:
6 Mutation-related TKI resistance is common in patients with CML Up to one in five newly-diagnosed CP-CML patients who start first-line TKI therapy will develop a BCR-ABL1 mutation Ai J, et al. Ther Adv Hematol. 2014;4:
7 Physicians do not always test for mutations according to guideline recommendations According to a 2010 survey of 507 physicians treating patients with CML 1 * Nearly half would not test for BCR-ABL1 KD mutations in patients not achieving MMR two years after the initiation of TKI therapy 1 9% indicated that they were unfamiliar with, never ordered, or did not have access to the test for BCR-ABL1 KD mutations 1 Many clinicians do not appreciate the role of mutation analysis in the overall management of CML 2 *Prospective United States-based, noninterventional, cross-sectional study conducted through an online survey in December Kantarjian HM, et al. Clin Lymphoma Myeloma Leuk. 2013;13: Ai J, Tiu RV. Ther Adv Hematol. 2014;5:
8 Single Mutations
9 Over 90 BCR-ABL1 point mutations have been identified that affect sensitivity to certain TKIs 1242T M244V L248V G250E/R Q252R/H Y253F/H E255K/V D276G T277A E279K V280A V289A/I F311L/I T315I F317L/V/I/C Y320C L324Q F359V/I/C/L D363Y L364I A365V A366G L370P V371A E373K S417F/Y I418S/V A433T S438C E450K/G/A/V E453G/K/V/Q E459K/V/G/Q P-loop SH3 contact SH2 contact A-loop M237V E258D W261L L273M E275K/Q E292V/Q I293V L298V V299L Y342H M343T A344V A350V M351T E355D/G/A Data from patients resistant to first-generation TKI therapy, collated from 27 studies published between 2001 and V379I A380T F382L L384M L387M/F/V M388L Y393C H396P/R/A A397P M472I P480L F486S E507G Star indicates amino acid position reported to be directly involved in first-generation TKI binding via hydrogen bonds or van der Waals interactions. Soverini S, et al. Blood. 2011;118:
10 Spectrum and frequency of BCR-ABL1 KD mutations recovered after TKI therapy Lighter color corresponds to the first amino acid change; darker color corresponds to the second amino acid change, if applicable. Cortes J, et al. Blood. 2007;110:
11 Higher number of mutations were associated with poor survival and 4 year EFS According to a single-center study of 207 patients with chronic phase, accelerated phase, or blast phase CML who failed first-line TKI, those with >1 BCR-ABL1 mutation exhibited worse response rates and long-term outcomes with TKI therapy compared with those with 1 BCR-ABL1 mutation. Among patients with 0, 1, or >1 BCR-ABL1 mutation 1 : 4-year EFS were 56%, 49%, and 0%, respectively (P=0.02) Overall survival rates were 91%, 69%, and 75%, respectively (P=0.13) 1. Quintas-Cardama A, et al. Haematologica. 2011;96(6):
12 NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines ) treatment recommendations based on BCR-ABL1 mutations Mutation present 2L and subsequent therapy options Y253H E255K/V F359V/C/I F317L/V/I/C V299L T315A T315I DAS, BOS DAS, BOS DAS, BOS NIL, BOS NIL NIL, BOS PON, OMA, HCT, or clinical trial Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Chronic Myeloid Leukemia V National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 12
13 ELN guidelines: Treatment recommendations based on BCR-ABL1 mutations In vitro sensitivity based on select BCR-ABL1 mutations* Mutation present Second-generation TKI IC50, range (nm) NIL DAS BOS PON Y253H NA 6.2 E255K E255V F359V F317L F317V 350 NA NA 10 V299L NA T315A NA 760 NA 1.6 T315I 697 to >10, to > *Per the ELN guidelines, one factor to take into consideration when considering switching TKIs is the presence and type of mutation. Baccarani M, et al. Blood. 2013;122:
14 The probability of TKI-resistant mutations may increase as the line of therapy increases and CML disease progresses Although patients may develop resistance to TKI therapy at any time, the risk of developing additional mutations may increase as patients move to later lines of TKI therapy and as the disease progresses 1 Up to 80% of patients with BP-CML have mutations 2 83% of first-generation TKI-resistant patients who relapsed while on a secondor third-line TKI experienced an emergence of newly acquired BCR-ABL1 mutations 3 1. Bauer RC, et al. Clin Cancer Res. 2013;19: Soverini S, et al. Blood. 2011;118: Soverini S, et al. Blood. 2009;114:
15 Compound Mutations
16 Compound mutations CML cells BCR-ABL1 compound mutations 1 Treatment with multiple TKIs may select for compound mutations ( 2 mutations in the same BCR-ABL1 molecule) that confer resistance to multiple TKIs 1,2 In vitro data suggest that compound mutations can be highly resistant to certain TKIs 3 1. Khorashad JS, et al. Blood. 2013;121: Shah NP, et al. J Clin Invest. 2007;117: O Hare T, et al. Nat Rev Cancer. 2012;12:
17 Sequential therapy may increase the probability of compound mutations 1 1. Shah et al. J Clin Invest. 2007;117:
18 Mutation Testing
19 Sensitivity A variety of mutational analysis techniques exist Method Sensitivity Pros Cons Direct (Sanger) 15-25% Mutation characterization Semiquantitative Bidirectional conformation of mutations Least sensitive (but sensitive enough for general use) High Resolution Melt (HRM) analysis 5-10% Pyrosequencing 5% Denaturing High Pressure Liquid Chromatography (DHPLC) High throughput Cost effective DNA Spiking not required No additional steps required after the PCR step Ideal for large scale screening High sensitivity and specificity Quantitative Internal quality and negative controls Allele-specific, High sensitivity Abbreviations: oligonucleotide AP, accelerated phase; % BP, blast phase; Quantitative CP, chronic phase. (ASO)-PCR Easy to perform 1% Alikian M, et al. Am J Hematol. 2012; 87: High throughput Cost effective Good for large scale studies Unable to characterize the mutations Optimal function requires small amplicon size which implies several (4-5) PCR reactions Short read length Prior mutations knowledge is required Labor intensive Unable to characterize the mutations Wild Type DNA Spiking required Prone for contamination Requires several PCR amplifications to obtain amplicons of ideal size Occurrence of non-specific peaks making data interpretation difficult Sensitivity could be compromised by closely located mutations Requires prior knowledge of mutations False positives issue Labor intensive if screening for multiple mutations 19
20 Clinical conditions and the presence of BCR-ABL1 mutations Mutation analysis in 399 patients with CP-CML receiving first-line, first-generation TKI Clinical condition Patients tested for mutations, n Presence of 1 BCR-ABL1 mutations (%) Failure (27) No CHR at 3 mo 16 3 (19) No CyR at 6 mo 9 1 (11) No PCyR at 12 mo 24 4 (17) No CCyR at 18 mo 36 6 (17) Loss CCyR (31) Loss CHR (50) Suboptimal (5) No CyR at 3 mo 15 1 (7) No PCyR at 6 mo 20 1 (5) No CCyR at 12 mo 51 5 (8) No MMR at 18 mo 52 0 (0) Loss MMR (but not CCyR) 95 4 (4) Soverini S, et al. Blood. 2011;118:abstract
21 Sanger sequencing is the most extensively used technique Direct (Sanger) sequencing is currently the most extensively used technique to detect BCR-ABL1 mutations 1,2 Least sensitive method, but sufficient for general use Several contract labs offer this service Sanger can be useful for predicting the best course of treatment for TKI-resistant patients and for monitoring resistant mutations in subsequent treatment settings 2,3 1. Baccarani M, et al. Blood. 2013;122: Alikian M, et al. Am J Hematol. 2012; 87: Soverini S, et al. Blood. 2011;118:
22 Sanger sequencing may not detect all mutations present T315I F359V F317L Y253H E255V E255K F359C Mutations detectable by Sanger sequencing (n=169) Low-level mutations detectable by massspectrometry assay only (n=132) Mutation testing performed after failure with a firstgeneration TKI prior to treatment with secondgeneration TKIs (n=220) Mutations that would influence therapeutic decisions after failure with a first-generation TKI were found in more patients with mass spectrometry than direct sequencing (32% vs 23%; P=0.03) Frequency of mutations (%) 10 Parker WT, et al. J Clin Oncol. 2011;29:
23 Low-level mutations can influence failure-free survival in CP-CML patients treated with second-generation TKIs after failure with a first-generation TKI Probability of failure-free survival (%) 100 No mutations (n=38) 80 Mutations by sequencing (n=9) Low-level mutations by mass spectrometry (n=6) Months since start of second-line therapy Parker WT, et al. J Clin Oncol. 2011;29:
24 NGS provides a higher level of sensitivity to detect clinically relevant BCR-ABL1 mutations that are not detected by Sanger sequencing 1 NGS performs ultra-deep sequencing (UDS) of the BCR-ABL1 kinase domain 2 UDS provides increased sensitivity and dissects qualitatively and quantitatively the clonal texture of the mutated BCR-ABL1 positive subpopulations 2 NGS is comprehensively selective for mutations that likely contribute to disease pathogenesis 3 For example, NGS identifies potential driver mutations (genetic alterations that provide the cell with a survival advantage), while filtering out passengers (mutations that can be expected to have no effect on cell survival) 3 1. Molecular MD. Accessed December Baccarani M et al. ASCO. 2014: Shuen A, Foulkes WD. Curr Onc. 2010;17(5):
25 Proportion of patients, % NGS detects more mutations than Sanger sequencing Sanger NGS No mutations Mutations 2 mutations Baseline mutation status. 267 patients with CP-CML resistant/intolerant to at least 2 prior TKIs or with the T315I mutation. Deininger MW, et al. Blood. 2016;127:
26 Deep sequencing (DS) may detect mutations earlier than conventional sequencing 51 patients treated with second-generation TKIs for a median of 9 months following failure of a first-generation TKI acquired BCR-ABL1 mutations detected by conventional sequencing Previously collected samples were analyzed for mutations using DS In 23 patients (45%), DS identified mutations that may confer resistance following failure of a first-generation TKI Median interval between detection by DS and conventional sequencing: 3 months (range, 1-9 months) Response status (as per ELN 2013 guideline) at the time of mutation detection by DS was Optimal (n=1), Warning (n=13), Failure (n=4); 5 patients had mutations at baseline (i.e., after failure of a firstgeneration TKI) Results suggest that mutation testing using DS may be useful for patients with Warning during second-line therapy Soverini S, et al. Blood. 2014;124: Abstract
27 Guideline Recommendations
28 Mutational analysis may provide additional information for patients with inadequate response The presence of mutations remains a consideration when making treatment decisions 1 Routine monitoring of BCR-ABL1 transcripts, in conjunction with cytogenetic evaluation, provides important information about long-term disease control in patients with CML 2 National Comprehensive Cancer Network (NCCN ) and ELN guidelines do not recommend a specific technique 1,2 Recommendations on When to Perform Mutational Analysis ELN 1,3 : In case of treatment failure or progression to AP or BP NCCN 2 : CP-CML - Failure to reach response milestones - Any sign of loss of response (defined as hematologic or cytogenetic relapse) - 1-log increase in BCR-ABL1 transcript levels and loss of MMR Disease progression to AP or BP IS, International Scale. 1. Baccarani M, et al. Blood. 2013;122: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Chronic Myeloid Leukemia V National Comprehensive Cancer Network, Inc All rights reserved. Accessed January 20, To view the most recent and complete version of the guideline, go online to NCCN.org. 3. Soverini S, et al. Blood. 2011;118:
29 Analysis of mutations in CP-CML Mutations studies can help make treatment decisions in the event of cytogenetic or hematologic relapse 1,2 Certain mutations confer resistance to certain TKIs 1,2 There is currently no role for mutation analysis at diagnosis or in patients with adequate response to therapy 1,2 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Chronic Myeloid Leukemia V National Comprehensive Cancer Network, Inc All rights reserved. Accessed January 20, To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Soverini S, et al. Blood. 2011;118:
30 Treatment options for TKI-resistant CML The results of mutational analysis is one of many factors (eg, efficacy, safety, patient comorbidities, cost) in making treatment decisions 1 For patients with TKI-resistant CML, potential treatment options include 2-4 : Alternate TKI Protein synthesis inhibitors Allogeneic hematopoietic stem cell transplantation (HCT) Clinical trial 1. Ai et al. Ther Adv Hematol. 2014;5: Baccarani M, et al. Blood. 2013;122: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Chronic Myeloid Leukemia V National Comprehensive Cancer Network, Inc All rights reserved. Accessed January 20, To view the most recent and complete version of the guideline, go online to NCCN.org. 4. Baccarani M, et al. Ann Oncol. 2012;23(Suppl7):vii
31 Summary
32 Summary Mutations in the BCR-ABL1 kinase domain may emerge at any time during TKI therapy and confer treatment resistance 1-7 The type of mutation can help determine the most appropriate subsequent therapy 8 Despite its recommendation in current treatment guidelines, mutational analysis is not always performed in patients with suspected TKI resistance 8,9 Mutational analysis, as recommended in current treatment guidelines, should be considered a standard part of monitoring CML patients treated with TKIs 8, Soverini S, et al. Clin Cancer Res. 2006;12: Cortes J, et al. Blood. 2007;109: Bixby D, et al. Leukemia. 2011;25: Bowlin SJ, et al. ASCPT Quintás-Cardama A, et al. Cancer Control. 2009;16: Valent P. Biologics. 2007; 1: Corbin AS, et al. J Clin Invest. 2011;12: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Chronic Myeloid Leukemia V National Comprehensive Cancer Network, Inc All rights reserved. Accessed January 20, To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 9. Kantarjian HM, et al. Clin Lymphoma Myeloma Leuk. 2013;13: Ai J, Tiu RV. Ther Adv Hematol. 2014;5: Baccarani M, et al. Blood. 2013;122: Soverini S, et al. Blood. 2011;118:
33 All trademarks are the property of their respective owners ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved. DS/0216/0025/US(3)
THE IMPORTANCE OF MUTATIONAL ANALYSIS IN CHRONIC MYELOID LEUKAEMIA FOR TREATMENT CHOICE
THE IMPORTANCE OF MUTATIONAL ANALYSIS IN CHRONIC MYELOID LEUKAEMIA FOR TREATMENT CHOICE *Hugues de Lavallade, 1,3 Aytug Kizilors 2,3 1. Department of Haematological Medicine, King s College Hospital, London,
More informationULTRA-DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN FOR BETTER THERAPEUTIC TAILORING OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA PATIENTS
ULTRA-DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN FOR BETTER THERAPEUTIC TAILORING OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA PATIENTS Simona Soverini, PhD Department of Experimental, Diagnostic and
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationIS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London
IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London Tell me generals, are we politicians necessary? I have to admit defeat before starting
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationTyrosine kinase inhibitors (TKIs) act by preventing disease
SUBJECT REVIEW Emergence of BCR-ABL Kinase Domain Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors Iulia D. Ursan, PharmD; Ruixuan
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationEvaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationClinical Significance of ABL Kinase Domain Mutation in Chronic Myeloid Leukemia under Imatinib Therapy.
Clinical Significance of ABL Kinase Domain Mutation in Chronic Myeloid Leukemia under Imatinib Therapy 1 Amr A.Ghannam, Abdou S. M. 2 and Mona Hatata 2 1 Department of Clinical Oncology, Tanta university
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Sensitive Detection of BCR-ABL1 in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationLAL: significato clinico e biologico delle mutazioni di Bcr-Abl
LAL: significato clinico e biologico delle mutazioni di Bcr-Abl Simona Soverini Dipartimento di Ematologia e Scienze Oncologiche L. e A. Seràgnoli Università di Bologna The vast majority of Ph+ ALL patients
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationSupplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationPATIENTS IN FOCUS: WHAT S RELEVANT FOR CHRONIC MYELOID LEUKAEMIA AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA?
PATIENTS IN FOCUS: WHAT S RELEVANT FOR CHRONIC MYELOID LEUKAEMIA AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA? This satellite symposium took place on 22 nd June 2017 as part of the
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationBCR-ABL1 Kinase Domain Mutation Status (including educational clinical scenario)
BCR-ABL1 Kinase Domain Mutation Status 171802 (including educational clinical scenario) Issue date: 23rd February 2018 Closing date: 23rd March 2018 Results for the BCR-ABL1 Kinase Domain Mutation Status
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2018 Related Policies: None BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Description In the treatment of Philadelphia chromosome positive leukemias,
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationTemplate for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)
Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Version: CMLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is
More informationEVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib Mustafa Daghistani Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road,
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More information"Molecular Monitoring Strategies to Track Response to BCR-ABL Kinase Inhibitors in CML"
Association of Molecular Pathology USCAP Companion Meeting Sunday, February 12, 2006 7:00 PM Dan Jones, MD, PhD Associate Professor Medical Director, Molecular Diagnostic Laboratory Division of Pathology
More informationBOSULIF (bosutinib) oral tablet
BOSULIF (bosutinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationChronic myeloid leukemia cells acquire resistance to tyrosine kinase
ARTICLE Chronic Myeloid Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationOriginal Study. Abstract
Original Study The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting Nicholas J. Di Bella,
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationIran J Cancer Preven May; 8(3):e2334. Published online 2015 May 27. Research Article
Iran J Cancer Preven. 2015 May; 8(3):e2334. Published online 2015 May 27. Research Article Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic
More informationSuboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
REVIEW IMATINIB TREATMENT FOR CHRONIC MYELOID LEUKEMIA Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? ELIAS JABBOUR, MD; JORGE E. CORTES,
More informationKinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
International journal of Biomedical science ORIGINAL ARTICLE Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
More informationMolecular monitoring in chronic myeloid leukemia how low can you go?
CHRONIC MYELOID LEUKEMIA Molecular monitoring in chronic myeloid leukemia how low can you go? Susan Branford Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationKwan, TK; Ma, ESK; Chan, YY; Wan, TSK; Liu, HSY; Sim, JPY; Yeung, YM; Lie, AKW; Yip, SF
Title Author(s) BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail Kwan, TK; Ma, ESK;
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationChronic Myelogenous Leukemia
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Chronic Myelogenous Leukemia Version 1.2015 NCCN.org Continue Version 1.2015, 08/28/14 National Comprehensive Cancer Network, Inc. 2014,
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2019 Related Policies: None BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Description In the treatment of Philadelphia chromosome positive
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationMeasuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia
Review Article Measuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia Jerald P. Radich, MD In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationQ&A and Technical Support Opening Remarks. Opening Remarks. Susan L. Buchanan, MS, PA-C Dana-Farber Cancer Institute
Susan L. Buchanan, MS, PA-C Dana-Farber Cancer Institute Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute August 7, 2015 Moderated by Rose K. Joyce NCCN, Conferences and Meetings Department This
More informationWafaa H. El-Metnawy 1, Mervat M. Mattar 2, Yasser H. El-Nahass 3, Mohamed A. Samra 4, Hala M. Abdelhamid 2, Raafat M. AbdlFattah 4, Ahmad R.
International journal of Biomedical science ORIGINAL ARTICLE Predictive Value of Pretreatment BCR-ABL IS Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic
More informationDecision Making in CML 2010
Decision Making in CML 2010 Imatinib is the standard treatment for chronic myeloid leukaemia (CML), but approximately 25% of patients are resistant or non-responsive to imatinib. 1 While physicians have
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationAdecade ago imatinib mesylate, the first tyrosine
CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATIINIB Monitoring disease response to tyrosine kinase inhibitor therapy in CML Timothy P. Hughes 1 and Susan Branford 1 1 Centre for Cancer Biology, Departments
More informationChronic Myelogenous Leukemia
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Chronic Myelogenous Leukemia Version 3.2014 NCCN.org Continue Version 3.2014, 01/15/14 National Comprehensive Cancer Network, Inc. 2014,
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationOverview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program
Overview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program Time slots Sessions Location June 9 th (Thursday) 8.00 10.00 Satellite Symposium: Improving outcomes: individualising
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More information